Video
Dr. Strosberg Discusses Trials in Neuroendocrine Tumors
Author(s):
In Partnership With:
Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).
Jonathan Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses trials in neuroendocrine tumors (NETs).
The NETTER-1 study randomized patients to receive Lutetium Lu 177 dotatate (Lutathera) with octreotide in patients with progressive midgut NETs. The TELESTAR trial randomized patients with diarrhea related to carcinoid syndrome to receive telotristat (Xermelo) versus placebo which lowered the incidence of diarrhea.
Currently, there are several accruing clinical trials, one of them being ECOG 2211, which is looking at temozolomide plus capecitabine versus temozolomide monotherapy in patients with progressive pancreatic NETs.
